The upgrade is based on Moody’s expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company’s incretin portfolio, which includes ...

Rocketing demand, legal disputes, and the future of weight loss were all spurred by a new class of anti-obesity medications.